Riad Mohammed Abdelrahman

Dr. Riad Mohammed Abdelrahman

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of Obesity
Verified
Journal Article
Open access
RARiad Mohammed Abdelrahman
Riad Mohammed Abdelrahman
TMTaha Musa
Taha Musa
IAIsmail Adam Arbab
Ismail Adam Arbab
MHMohsen Hussein
Mohsen Hussein
EAEltieb Omer Ahmed
Eltieb Omer Ahmed
SGSahar Ibrahim Gasmallah
Sahar Ibrahim Gasmallah
Background: Obesity has emerged as a pressing global health challenge, and therapies based on glucagon‐like Peptide 1 receptor agonists (GLP‐1RAs) have transformed its management. Currently, liraglutide, semaglutide, and tirzepatide are FDA‐approved for obesity treatment, while other agents are used off‐label. These drugs not only provide unprecedented efficacy and acceptable safety in weight reduction and glycemic control for patients with obesity and Type 2 diabetes but also hold promise in broader indications, including neurodegenerative disorders, fatty liver disease, dyslipidemia, atherosclerosis, and cardiovascular conditions. Methods: This narrative review examined the therapeutic applications of GLP‐1RAs for obesity, emphasizing their efficacy, safety profile, challenges with patient adherence, and limitations. The review also explored emerging innovations such as ultralong‐acting formulations, combination therapies, and the integration of digital health and artificial intelligence in advancing antiobesity drug development. Results: GLP‐1RAs represent a paradigm shift in the treatment of obesity and metabolic diseases, with rapidly expanding indications and global uptake. Recent evidence highlights improvements in tolerability, global accessibility, and the potential of novel technologies to optimize patient outcomes. By 2025, GLP‐1RAs are anticipated to receive FDA approval for new indications, such as chronic kidney disease, heart failure with preserved ejection fraction, and metabolic dysfunction–associated steatohepatitis. Novel agents including CagriSema and higher dose oral semaglutide are advancing through clinical trials, while pivotal trial results for orforglipron, mazdutide, retatrutide, and survodutide are anticipated to further expand the therapeutic landscape. At the same time, the arrival of generic liraglutide and evolving insurance coverage are reshaping access and affordability. Conclusion: The convergence of pharmacological innovation, digital health strategies, and equitable care initiatives is expected to revolutionize obesity therapeutics in the coming decade. Priorities for future research include sustaining long‐term weight loss, establishing disease‐modifying potential in nonmetabolic disorders, and addressing health equity concerns to ensure broader global benefit.

27 March 2026 in Obesity Medicine
Verified
Journal Article
Closed access
RARiad Mohammed Abdelrahman
Riad Mohammed Abdelrahman
TMTaha Hussein Musa
Taha Hussein Musa
IAIsmail Adam Arbab
Ismail Adam Arbab
EAEltieb Omer Ahmed
Eltieb Omer Ahmed
SGSahar Ibrahim Gasmallah
Sahar Ibrahim Gasmallah
WAWafaa Ramadan Ahmed
Wafaa Ramadan Ahmed

5 September 2025 in Obesity Medicine
Verified
Journal Article
Closed access
RARiad Mohammed Abdelrahman
Riad Mohammed Abdelrahman
SSSuleiman I. Sharif
Suleiman I. Sharif
TMTaha Hussein Musa
Taha Hussein Musa
HMHassan Hussein Musa
Hassan Hussein Musa
IAIsmail Adam Arbab
Ismail Adam Arbab
EAEltieb Omer Ahmed
Eltieb Omer Ahmed

26 September 2025 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
RARiad Mohammed Abdelrahman
Riad Mohammed Abdelrahman
AAAzmi Mohamed Ali Abdallah
Azmi Mohamed Ali Abdallah
AAAyaz Ahmed Ahmed
Ayaz Ahmed Ahmed
TMTaha Hussien Musa
Taha Hussien Musa
IAIsmail Adam Arbab
Ismail Adam Arbab
HAHuda Babikir Ahmed
Huda Babikir Ahmed
Background: Chronic Kidney Disease (CKD) complications, like cardiovascular complications, are one of the leading causes of mortality. Managing the biochemical profile is essential in slowing the progression of CKD and its associated consequences. This study aimed to assess the effect of cinacalcet add-on therapy on clinical outcomes in patients with End-Stage Renal Disease (ESRD) on Hemodialysis (HD) who developed Secondary Hyperparathyroidism and are receiving hemodialysis. Method: A mixed retrospective-prospective cohort multicenter study was conducted in three hospitals in Saudi Arabia between December 1st, 2019, and January 31st, 2021. Results: One hundred and seventy-four subjects were analyzed; the incidence of the cardiovascular events and the first cardiovascular events in patients on cinacalcet was significantly decreased compared to the patients on the conventional therapy ( p = 0.02 & 0.005, respectively ). The incidence of coronary artery diseases was significantly decreased by 61% in the patients on cinacalcet ( HR = 0.39 , p = 0.04). Patients on Cinacalcet were 69% less in all-cause first hospitalization hazard ratio; HR = 0.31 , 95% CI: 0.16–0.63 , p = 0.001. There was no significant reduction in the risk of all-cause and cardiovascular mortality in the patients on Cinacalcet ( p = 0.06 & 0.12, respectively ), but patients with Hypertension and “Diabetes Mellitus & Hypertension” etiology had a lower mortality HR (Hypertension: HR = 0.46 , 95% CI = 0.21-1.00 , p = 0.05; “Diabetes Mellitus & Hypertension”: HR = 0.42 , 95% CI = 0.2-1.00 , p = 0.04). There was no significant difference in the frequency of incidence of bone fractures between the two groups ( p = 0.26). Conclusion: Cinacalcet is superior in decreasing the frequency of cardiovascular events. However, it is not effective in reducing the risk of all-cause and cardiovascular mortality, except in patients with “Hypertension” and “Diabetes Mellitus & Hypertension” etiology, and it might offer a somewhat protective trend in males and older patients. Clinical trial number: Not applicable.

13 August 2025 in Frontiers in Nephrology
Verified
Journal Article
Open access
PDF file
RARiad Mohammed Abdelrahman
Riad Mohammed Abdelrahman
TMTaha H. Musa
Taha H. Musa
CMChiamaka Linda Mgbechidinma
Chiamaka Linda Mgbechidinma
EAEltieb Omer Ahmed
Eltieb Omer Ahmed
Background: Calcimimetics are a group of medications that increase the sensitivity of the calcium receptors to extracellular calcium ions and inhibit the release of parathyroid hormone (PTH) in patients with chronic kidney disease (CKD).Objectives: The aim of this study was to analyze the global trends in the publication of articles on calcimimetics through bibliometric analysis of the Web of Science and Scopus databases, as well as to identify the most highly cited articles from 1997 to 2024.Methods: Systematic and thematic analyses were performed to provide substantial insights into calcimimetic research. Data were analyzed using VOS viewer (var1.6.6) and the Biblioshiny tool.Results: A total of 3,500 documents were identified for analysis. There was an exponential growth in calcimimetic-associated publications (from 57 documents in 2004 to 258 in 2021). The mean of the total citations per article showed a decrease from 226 in 1998 to 0 in 2024. The United States was the most productive country. Goodman W. emerged as the most prolific author, with high-level metrics [n = 45, total number of citations (TNC) = 4,768, h_index = 27]. Fukazawa M. showed the longest research activity in the field, with 97 published documents in 25 years. Nephrology Dialysis Transplantation was the most published journal, with 112 documents and with an h_index of 43. The thematic KeyWords Plus analysis identified three key domains, including pharmacological targets (CaSR and cinacalcet) reported in niche themes and central CKD and mineral bone disorder (MBD) pathway (hemodialysis, vascular calcification, and vitamin D) case reports in emerging/declining themes. The small correlation between “diabetes” and “mineral metabolism” (despite shared CKD complications) suggests a critical research gap. While our thematic map highlighted robust research on the pathophysiology of CKD-MBD, critical clinical outcomes remain underexplored. Future trials should highlight these gaps, particularly in high-risk subgroups such as diabetic patients with CKD.Conclusion: The results of this review offer a summary of the global landscape, the key research areas, and possible future directions in calcimimetic research. This information can assist researchers in exploring the knowledge structure and understanding future trends in calcimimetic research, as well as in supporting collaboration toward advanced global research on calcimimetics.

5 August 2025 in Research Square
Verified
Preprint
Open access
PDF file
RARiad Mohammed Abdelrahman
Riad Mohammed Abdelrahman
TMTaha Musa
Taha Musa
HMHassan Hussein Musa
Hassan Hussein Musa
SGSahar Ibrahim Gismallah
Sahar Ibrahim Gismallah
CMChiamaka Linda Mgbechidinma
Chiamaka Linda Mgbechidinma
MJMohammed Jalal
Mohammed Jalal
Background: Malaria, a life-threatening disease, remains a major public health challenge, particularly in Sudan, where it causes significant morbidity and mortality. Objectives: To comprehensively review and explore Malaria Research in Sudan in the Scopus database and identify the cited articles from 1956 to 2024. Methods A systematic and thematic analysis was made to provide a substantial insight into the most recent progressions, tracking the growth of research on malaria in Sudan, understanding key contributions of authors, countries, and institutions, and interpreting pattern’s themes, and emerging topics. Data were analyzed using VOS viewer, Var1.6.6, and the Biblioshiny tool. The correlation analysis was conducted using IBM SPSS 25 software, and a p-value ≤ 0.05 was considered statistically significant. Results: The conflict in Sudan has led to a resurgence of malaria, and effective malaria control efforts have been severely disrupted. 252 documents were identified for analysis. There was a continuous relatively steady trend in scientific output between 1978 and 2022 1978 and 2022, and the highest peak had been seen in 2004 (17 documents). The mean total citation per article increased from 0.2 in 1990 to a peak of 3.6 in 2014, declining to a bottom of 0.3 in 2023. Out of 71 contributed countries, Sudan was the most productive country with138 (55%) of articles. Adam I. from Faculty of Medicine, University of Khartoum, emerged as the most prolific author with high-level of metrics (n = 90, TNC = 2039, and h_index=26). Among the 105 peer reviewed journals; “Malaria Journal” was the most publishing journal (36 documents), TNC; 985, h_index of 18, and Journal Impact Factor (JIF, 2023) 2.4 score. “Malaria”, “Sudan”, and," plasmodium falciparum” are the most explored keywords by authors. Thematic mapping indicated that the emerging themes are focusing on “thrombocytopenia”, “anopheles stephensi”, “antibodies”, “animal”, and “non-human”. Keyword analysis did not highlight “ACT-resistant malaria” as an emerging theme or high-centrality topic. Conclusion: National and international efforts are needed for restarting malaria control. Our findings provide an overview of the global status, and potential trends in malaria in Sudan research. This information can assist researchers in exploring the knowledge structure and offer insights for future research on malaria in Sudan.